Stockscreener 앱 받기
47.03
0.32%
0.15
시간 외 거래:
47.12
0.09
+0.19%
전일 마감가:
$46.88
열려 있는:
$47.21
하루 거래량:
3.99M
Relative Volume:
0.53
시가총액:
$18.66B
수익:
$2.23B
순이익/손실:
$-3.19B
주가수익비율:
-5.7732
EPS:
-8.1462
순현금흐름:
$-1.60B
1주 성능:
+2.87%
1개월 성능:
-7.29%
6개월 성능:
+88.04%
1년 성능:
+79.09%
1일 변동 폭
$46.17
$48.67
1주일 범위
$45.95
$48.77
52주 변동 폭
$22.28
$59.55
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
47.03 | 18.60B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
FDA AdCom panel to review and vote on next COVID shots - Seeking Alpha
UBS reiterates Moderna stock rating on melanoma trial catalyst - Investing.com
UBS reiterates Moderna stock rating on melanoma trial catalyst By Investing.com - Investing.com Canada
Moderna Inc. stock (US60770K1034): Vaccine player back in focus after infectious disease headline - AD HOC NEWS
Moderna, Inc. (MRNA) Stock Analysis: Navigating a Biotech Giant with a 260% Revenue Growth - DirectorsTalk Interviews
Moderna stock (US60770K1034): mRNA specialist in focus after latest quarterly figures - AD HOC NEWS
MRNA Stock Quote Price and Forecast - CNN
Moderna Inc. (NASDAQ: MRNA) Stock Under Pressure as mRNA Platform Seeks New Applications - foreignpolicyjournal.com
Moderna director Noubar Afeyan sells $433,878 in stock By Investing.com - Investing.com Australia
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells $433,878.92 in Stock - MarketBeat
Moderna director Noubar Afeyan sells $433,878 in stock - Investing.com
Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise - Stock Titan
Moderna’s mRNA flu shot to get FDA review - The Hill
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting - BioPharma Dive
Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue RulesWhat's Changed - Yahoo Finance
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm - BioSpace
MRNA Technical Analysis | Trend, Signals & Chart Patterns | MODERNA INC (NASDAQ:MRNA) - ChartMill
Understanding Momentum Shifts in (MRNA) - Stock Traders Daily
Total liabilities & shareholders' equities of Moderna, Inc. – BVL:MRNAUS - TradingView
ASCO26: Merck & Co., Moderna detail melanoma survival findings for cancer vaccine - FirstWord Pharma
CapEx per share of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna stock (US60770K1034): analysts turn cautious after sharp 2026 rebound - AD HOC NEWS
Moderna mRNA flu vaccine to get FDA panel review - The Hill
FDA plans rare advisory hearing to debate Moderna’s flu shot - The Boston Globe
EBITDA per share of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna, Merck cancer combo cuts melanoma spread risk at five years - Reuters
[144] Moderna, Inc. SEC Filing - Stock Titan
Moderna's mRNA flu shot to face FDA panel in June - FirstWord Pharma
Moderna Flu Shot Heads To FDA Advisory PanelModerna (NASDAQ:MRNA) - Benzinga
Moderna, Inc. Income Statement – BVL:MRNAUS - TradingView
Asset turnover of Moderna, Inc. – BVL:MRNAUS - TradingView
Moderna, Inc. Cash Flow – BVL:MRNAUS - TradingView
MRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu Shot - Yahoo Finance
Moderna (MRNA) Flu Vaccine Review Scheduled by FDA for June 2024 - GuruFocus
Moderna's (MRNA) Flu Vaccine Set for FDA Advisory Panel Review - GuruFocus
Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June - marketscreener.com
US FDA to hold expert committee meeting to review Moderna's flu vaccine - Reuters
Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports - marketscreener.com
Moderna to face FDA AdCom review for flu shot (MRNA:NASDAQ) - Seeking Alpha
FDA Plans Rare Advisory Hearing to Debate Moderna’s Flu Shot - Bloomberg.com
Forget Moderna: This biotech juggernaut is a way better buy right now - MSN
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - Yahoo Finance
CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.
MRNA Stock Price, Quote & Chart | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna, Inc. Trade Ideas — LSX:A2N9D9 - TradingView
The next era of healthcare is personal - McKinsey & Company
Moderna stock (US60770K1034): Hantavirus headlines, Q1 revenue beat and lingering volatility - AD HOC NEWS
Moderna's revenues see strong international momentum in Q1 earnings - MSN
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform - BioSpace
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain - TradingView
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
May 21 '26 |
Sale |
46.84 |
9,263 |
433,879 |
3,924 |
0.98%
0.12%
자본화:
|
볼륨(24시간):